Innoviva Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Innoviva Inc 's ROA in the second quarter of 2026?
Innoviva Inc achieved a return on average assets (ROA) of 19.99 % in its second quarter of 2026, this is above INVA's average return on assets of 16.91%.
Innoviva Inc assets over the 12 months ending in its second quarter of 2026 are valued at $1,787 million

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 46 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 121, from total ROA ranking in the first quarter of 2026 at 278.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	67.85 %	46.17 %	25.41 %	16.08 %	8.89 %
Y / Y Net Income Change	-	-	707.36 %	7312.04 %	-
Net Income (TTM) in million	357	504	271	127	39
Return On Assets (TTM)	19.99 %	32.33 %	19.16 %	9.56 %	3.01 %
INVA's Total Ranking	# 121	# 278	# 638	# 1572	# 3051
Total Assets (TTM) in million	2,242	1,837	1,635	1,433	1,336
Seq. Total Assets Change	22.09 %	12.32 %	14.14 %	7.24 %	6.32 %
Seq. Net Income Change	-	13.67 %	82.58 %	41.17 %	-

INVA's 5 Years Annual ROA >> Back to INVA Management Effectiveness >> Compare INVA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 26
Sector	# 47
Overall	# 205

Return On Assets Statistics
High	Average	Low
112.77 %	16.91 %	-35.68 %
(Dec 31 2018)		(Jun 30 2014)

Financial Statements
Innoviva Inc 's Assets	$ 2,242 million	INVA's Balance sheet
Innoviva Inc 's Income	$ -83 million	Quarterly INVA's Income Statement
INVA's Income by Division		See INVA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	56.44 %	3.27 %	2.36 %	32.97 %	-7.19 %
Total Assets in million	2,040	1,304	1,262	1,233	928
Y / Y Net Income Change	1059.22 %	-86.98 %	-18.41 %	-40.28 %	25.53 %
Net Income in million	271	23	180	220	369
Annual Return On Assets	13.29 %	1.79 %	14.24 %	17.86 %	39.77 %

INVA's 5 Years Annual ROA >> Back to INVA Management Effectiveness >> Compare INVA ROA to its Competitors

Comment on INVA's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 13.29 % compared to prior year, due to annual net income growth of 1059.22 % to $271.17 million, while value of Innoviva Inc 's overall assets grew just by 56.44 % to $2,039.66 million, compared to $2,039.66 a year before.

More Return On Assets Ratios
INVA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
INVA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for INVA's Competitors
Subscribers only: Roa for Innoviva Inc 's Suppliers
Subscribers only: Return On Assets for INVA's Customers

You may also want to know
INVA's Roi	INVA's Inventory Turnover Ratio	INVA's Growth Rates	INVA's Dividend Comparisons
	INVA's Profitability Ratios	INVA's Asset Turnover Ratio	INVA's Dividend Growth
INVA's Roe	INVA's Valuation Ratios	INVA's Financial Strength Ratios	INVA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %
Tg Therapeutics Inc	33.59 %
Meiragtx Holdings Plc	29.37 %
Indivior Pharmaceuticals Inc	28.21 %
Qhslab Inc	27.12 %
Adma Biologics Inc	26.58 %
Mettler toledo International Inc	24.86 %
Medpace Holdings Inc	24.84 %
Caredx Inc	24.81 %
Acadia Pharmaceuticals Inc	24.38 %
Eli Lilly And Company	21.97 %
Innoviva Inc	21.64 %
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %

Date modified: 2026-09-11T18:47:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.